These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 19109335)

  • 21. Evaluation of the mutant selection window for fluoroquinolones against Neisseria gonorrhoeae.
    Allen GP; Hankins CD
    J Antimicrob Chemother; 2009 Aug; 64(2):359-63. PubMed ID: 19460783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams.
    Behra-Miellet J; Dubreuil L; Jumas-Bilak E
    Int J Antimicrob Agents; 2002 Nov; 20(5):366-74. PubMed ID: 12431872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans.
    Manavathu EK; Ramesh MS; Baskaran I; Ganesan LT; Chandrasekar PH
    J Antimicrob Chemother; 2004 Feb; 53(2):386-9. PubMed ID: 14729762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of biofilm of strains isolated from patients with chronic obstructive pulmonary disease by levofloxacin, moxifloxacin, ciprofloxacin, amoxicillin/clavulanic acid and ceftriaxone.
    Drago L; Mattina R; Legnani D; Romano CL; Vianello E; Ricci C; De Vecchi E
    Int J Immunopathol Pharmacol; 2011; 24(4):1027-35. PubMed ID: 22230408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of antifungal efficacies of moxifloxacin, liposomal amphotericin B, and combination treatment in experimental Candida albicans endophthalmitis in rabbits.
    Deren YT; Ozdek S; Kalkanci A; Akyürek N; Hasanreisoğlu B
    Can J Microbiol; 2010 Jan; 56(1):1-7. PubMed ID: 20130687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
    Huelves L; Sevillano D; Martínez-Marín C; López-Casla MT; Gracia M; Alou L; del Carmen Ponte M; Prieto J; Soriano F;
    Int J Antimicrob Agents; 2006 Apr; 27(4):294-9. PubMed ID: 16527462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Laboratory detection of Haemophilus influenzae with decreased susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin due to GyrA and ParC mutations.
    Pérez-Vázquez M; Román F; Aracil B; Cantón R; Campos J
    J Clin Microbiol; 2004 Mar; 42(3):1185-91. PubMed ID: 15004073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro and in vivo activities of fluoroquinolones against Aeromonas hydrophila.
    Ko WC; Chiang SR; Lee HC; Tang HJ; Wang YY; Chuang YC
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2217-22. PubMed ID: 12821471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo antifungal activities of DU-6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungi.
    Nakajima R; Kitamura A; Someya K; Tanaka M; Sato K
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1517-21. PubMed ID: 7492096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests.
    Barry AL; Fuchs PC; Brown SD
    Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):305-9. PubMed ID: 10385024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains.
    Farrell DJ; Liverman LC; Biedenbach DJ; Jones RN
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3631-4. PubMed ID: 21555765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
    Sirvent E; Ruiz M; Rodríguez JC; Royo G
    Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):603-7. PubMed ID: 17194384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [In vitro activity of linezolid, moxifloxacin, levofloxacin, clindamycin and rifampin, alone and in combination, against Staphylococcus aureus and Staphylococcus epidermidis].
    Soriano A; Jurado A; Marco F; Almela M; Ortega M; Mensa J
    Rev Esp Quimioter; 2005 Jun; 18(2):168-72. PubMed ID: 16130039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results?
    Galles AC; Jones RN; Sader HS
    J Chemother; 2008 Feb; 20(1):38-42. PubMed ID: 18343741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins.
    Brisse S; Milatovic D; Fluit AC; Verhoef J; Martin N; Scheuring S; Köhrer K; Schmitz FJ
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2051-5. PubMed ID: 10428935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
    Blondeau JM; Laskowski R; Bjarnason J; Stewart C
    Int J Antimicrob Agents; 2000 Feb; 14(1):45-50. PubMed ID: 10717500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections.
    Naber KG; Hollauer K; Kirchbauer D; Witte W
    Int J Antimicrob Agents; 2000 Nov; 16(3):239-43. PubMed ID: 11091042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
    Lopez H; Vilches V; Scarano S; Stepanik D; Smayevsky J; Lemme L; Cardeñosa O; Ambler J; Sucari A
    Int J Antimicrob Agents; 2001 Oct; 18(4):379-82. PubMed ID: 11691572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [In vitro antibiotic susceptibility to fluoroquinolones].
    Wong CA; Galvis V; Tello A; Villareal D; Rey JJ
    Arch Soc Esp Oftalmol; 2012 Mar; 87(3):72-8. PubMed ID: 22423655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model.
    Meletiadis J; Stergiopoulou T; O'Shaughnessy EM; Peter J; Walsh TJ
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2053-64. PubMed ID: 17387150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.